NCT00004180 2023-06-26
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Phase 2 Completed
Dana-Farber Cancer Institute
Université de Sherbrooke
University of Pittsburgh
Canadian Network for Observational Drug Effect Studies, CNODES
M.D. Anderson Cancer Center
Vanderbilt University
Massachusetts General Hospital